Tight control (achieved with insulin or oral medication) was associated with a 12 % lower risk of what the trial authors called “any diabetes-related endpoint” (that is, clinical end-points predefined by the researchers) and a 25 % lower risk of microvascular complications (including microalbuminuria). Here, INS is linked to diabetes mellitus.